274 related articles for article (PubMed ID: 26700874)
1. Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
Stubbe F; Agaimy A; Ott O; Lettmaier S; Vassos N; Croner R; Hohenberger W; Fietkau R; Semrau S
Cancer Radiother; 2016 Feb; 20(1):6-13. PubMed ID: 26700874
[TBL] [Abstract][Full Text] [Related]
2. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
[TBL] [Abstract][Full Text] [Related]
3. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy plus hyperthermia (CRTH) versus chemoradiotherapy (CRT) alone in neoadjuvant treatment of soft tissue sarcoma: tumor response, treatment toxicity and disease control.
Willner A; Agaimy A; Fechner K; Ott O; Denz A; Weissmann T; Meidenbauer N; Höfler D; Gaipl U; Frey B; Schmidt M; Haller F; Horch R; Hartmann A; Grützmann R; Fietkau R; Semrau S
Int J Hyperthermia; 2023; 40(1):2248424. PubMed ID: 37611915
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Interdigitated Chemoradiotherapy Using Mesna, Doxorubicin, and Ifosfamide for Large, High-grade, Soft Tissue Sarcomas of the Extremity: Improved Efficacy and Reduced Toxicity.
Chowdhary M; Sen N; Jeans EB; Miller L; Batus M; Gitelis S; Wang D; Abrams RA
Am J Clin Oncol; 2019 Jan; 42(1):1-5. PubMed ID: 29782358
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.
Brandts CH; Schulz C; Willich N; Steffen B; Hardes J; Gosheger G; Winkelmann W; Serve H; Heinecke A; Berdel WE; Thomas M
Cancer Chemother Pharmacol; 2012 Mar; 69(3):613-20. PubMed ID: 21947168
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas.
Mullen JT; Kobayashi W; Wang JJ; Harmon DC; Choy E; Hornicek FJ; Rosenberg AE; Chen YL; Spiro IJ; DeLaney TF
Cancer; 2012 Aug; 118(15):3758-65. PubMed ID: 22180344
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Bramwell V; Rouesse J; Steward W; Santoro A; Schraffordt-Koops H; Buesa J; Ruka W; Priario J; Wagener T; Burgers M
J Clin Oncol; 1994 Jun; 12(6):1137-49. PubMed ID: 8201375
[TBL] [Abstract][Full Text] [Related]
9. Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
Jebsen NL; Bruland ØS; Eriksson M; Engellau J; Turesson I; Folin A; Trovik CS; Hall KS
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1359-66. PubMed ID: 20933339
[TBL] [Abstract][Full Text] [Related]
10. Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.
Eckert F; Gani C; Kluba T; Mayer F; Kopp HG; Zips D; Bamberg M; Müller AC
Strahlenther Onkol; 2013 Jun; 189(6):482-5. PubMed ID: 23604183
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant concurrent chemoradiotherapy with and without hyperthermia in retroperitoneal sarcomas: feasibility, efficacy, toxicity, and long-term outcome.
Willner A; Fechner K; Agaimy A; Haller F; Eckstein M; Ott OJ; Putz F; Gaipl US; Kersting S; Meidenbauer N; Grützmann R; Fietkau R; Semrau S
Strahlenther Onkol; 2021 Dec; 197(12):1063-1071. PubMed ID: 34735576
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Mahmoud O; Dosch A; Kwon D; Pitcher JD; Conway S; Benedetto P; Fernandez G; Trent J; Temple HT; Wolfson AH
Am J Clin Oncol; 2016 Oct; 39(5):528-34. PubMed ID: 24879472
[TBL] [Abstract][Full Text] [Related]
13. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
14. [Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases].
Moureau-Zabotto L; Thomas L; Bui BN; Chevreau C; Stockle E; Martel P; Bonneviale P; Marques B; Coindre JM; Kantor G; Matsuda T; Delannes M
Cancer Radiother; 2004 Oct; 8(5):279-87. PubMed ID: 15561593
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control].
Sauer R; Schuchardt U; Hohenberger W; Wittekind C; Papadopoulos T; Grabenbauer GG; Fietkau R
Strahlenther Onkol; 1999 Jun; 175(6):259-66. PubMed ID: 10392166
[TBL] [Abstract][Full Text] [Related]
16. Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
Roeder F; Lehner B; Schmitt T; Kasper B; Egerer G; Sedlaczek O; Grüllich C; Mechtersheimer G; Wuchter P; Hensley FW; Huber PE; Debus J; Bischof M
BMC Cancer; 2014 May; 14():350. PubMed ID: 24885755
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
18. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
19. A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
Schmitt T; Lehner B; Kasper B; Bischof M; Roeder F; Dietrich S; Dimitrakopoulou-Strauss A; Strauss LG; Mechtersheimer G; Wuchter P; Ho AD; Egerer G
BMC Cancer; 2011 Dec; 11():510. PubMed ID: 22152120
[TBL] [Abstract][Full Text] [Related]
20. Long-term Outcomes With Ifosfamide-based Hypofractionated Preoperative Chemoradiotherapy for Extremity Soft Tissue Sarcomas.
Pennington JD; Eilber FC; Eilber FR; Singh AS; Reed JP; Chmielowski B; Eckardt JJ; Bukata SV; Bernthal NM; Federman N; Nelson SD; Dry SM; Wang PC; Luu M; Selch MT; Steinberg ML; Kalbasi A; Kamrava M
Am J Clin Oncol; 2018 Dec; 41(12):1154-1161. PubMed ID: 29664796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
